
European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis
The European Union (EU) marketing authorisation for the subcutaneous (SC) formulation of Remsima® (CT-P13) now applies to all previously approved indications for the intravenous (IV) […]
